Citations

Showing 10 of 108135 citations.

Incidence, Prevalence, and Mortality of Dermatomyositis: A Population‐Based Cohort Study
Kronzer, Vanessa L. , Kimbrough, Bradly A. , Crowson, Cynthia S. , Davis, John M. , Holmqvist, Marie , Ernste, Floranne C. , Holmqvist, Marie , Kronzer, Vanessa L , Davis, John M

Mayo Clinic

Arthritis Care & Research | September 22, 2021 | Volume: 75 | Issue: 2 | Pages: 348-355

10.1002/acr.24786 | PMID 34549549 Get It

ObjectiveWe aimed to determine the population‐based incidence, prevalence, and mortality of dermatomyositis (DM) using European Alliance of Associations for Rheumatology (EULAR)/American College of Rheumatology (ACR) criteria.MethodsThis population‐based cohort study included incident DM from January 1, 1995 to December 31, 2019. We manually reviewed all individuals with at least 1 code for DM or polymyositis to determine if they met EULAR/ACR criteria, subspecialty physician diagnosis, and/or Bohan and Peter criteria. We age‐ and sex‐adjusted incidence and prevalence estimates to the US non‐Hispanic White year 2000 population and estimated prevalence on January 1, 2015. Standardized mortality ratios (SMRs) with 95% confidence intervals (95% CIs) compared observed to expected mortality adjusting for age, sex, and year.ResultsWe identified 40 cases of verified DM, with 29 cases incident in Olmsted County from 1995 to 2019. The mean age was 57 years, 26 (90%) were female, and 12 (41%) had clinically amyopathic DM (CADM). The median follow‐up time was 8.2 years. The overall adjusted incidence of DM was 1.1 (95% CI 0.7–1.5) per 100,000 person‐years, and prevalence was 13 (95% CI 6–19) per 100,000. The SMR was significantly elevated among the myopathic DM cases (3.1 [95% CI 1.1–6.8]) but not CADM cases (1.1 [95% CI 0.2–3.3]). The positive predictive value of ≥2 DM codes was only 40 of 82 (49%).ConclusionThis population‐based study found that DM incidence and prevalence were higher than previously reported. Mortality was significantly elevated for myopathic DM but not for CADM.
Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia
Wieduwilt, Matthew J. , Metheny, Leland , Zhang, Mei‐Jie , Wang, Hailin , Estrada‐Merly, Noel, Marks, David I. , Al‐Homsi, A. Samer, Muffly, Lori , Chao, Nelson J. , Rizzieri, David A. , Gadalla, Shahinaz M. , Cairo, Mitchell S. , Gore, Steven D. , Patel, Sagar S. , Michelis, Fotios V. , Inamoto, Yoshihiro , Copelan, Edward A. , Palmisiano, Neil , Kharfan‐Dabaja, Mohamed A. , Ganguly, Siddhartha , Bredeson, Christopher , Ballen, Karen K. , Martino, Rodrigo , Wirk, Baldeep , Aljurf, Mahmoud , Bashey, Asad, Murthy, Hemant S. , Farhadfar, Nosha , Liu, Hongtao , Abdel‐Azim, Hisham , Solh, Melhem , Seftel, Matthew D. , Poel, Marjolein van der , Kamble, Rammurti T., Munker, Reinhold , Cahn, Jean‐Yves , Freytes, César O. , Krem, Maxwell M. , Winestone, Lena E. , Nathan, Sunita , Verdonck, Leo F. , Sharma, Akshay , Ringdén, Olle , Černý, Jan , Choe, Hannah , Seo, Sachiko , Baxter‐Lowe, Lee Ann , Hildebrandt, Gerhard , Litzow, Mark R. , Abid, Muhammad Bilal , Weisdorf, Daniel J. , Saber, Wael , Chao, Nelson , Rizzieri, David A , Gadalla, Shahinaz M , Bhatt, Vijaya Raj , Patel, Sagar , Michelis, Fotios V , Kharfan-Dabaja, Mohamed A , Savani, Bipin N , Martino, Rodrigo , Bacher, Ulrike , Liu, Hongtao , Waller, Edmund K , McGuirk, Joseph , Krem, Maxwell M , Winestone, Lena E , Olsson, Richard F , Sharma, Akshay , Ringden, Olov , Friend, Brian D , Cerny, Jan , Chhabra, Saurabh , Nishihori, Taiga , Seo, Sachiko , George, Biju , Baxter-Lowe, Lee Ann , Hildebrandt, Gerhard C , de Lima, Marcos , Litzow, Mark R. , Hourigan, Christopher S , Weisdorf, Dan , Murthy, Hemant S , Muffly, Lori , Abid, Muhammad Bilal , Gale, Robert Peter , Mussetti, Alberto , Bhatt, Vijaya Raj , Badawy, Sherif M. , Lazarus, Hillard M. , Díaz, Miguel Ángel , Cassaday, Ryan D. , Savani, Bipin N. , Yared, Jean A. , Aldoss, Ibrahim , Waller, Edmund K. , Grunwald, Michael R. , Liesveld, Jane L. , McGuirk, Joseph P. , Lee, Jong Wook , Gergis, Usama , Olsson, Richard F. , Chhabra, Saurabh , Nishihori, Taiga , Lima, Marcos de , Kebriaei, Partow , Hourigan, Christopher S.

Mayo Clinic

Blood Advances | September 21, 2021 | Volume: 6 | Issue: 1 | Pages: 339-357

10.1182/bloodadvances.2021004916 | PMID 34547770 Get It

Abstract The role of haploidentical hematopoietic cell transplantation (HCT) using posttransplant cyclophosphamide (PTCy) for acute lymphoblastic leukemia (ALL) is being defined. We performed a retrospective, multivariable analysis comparing outcomes of HCT approaches by donor for adults with ALL in remission. The primary objective was to compare overall survival (OS) among haploidentical HCTs using PTCy and HLA-matched sibling donor (MSD), 8/8 HLA-matched unrelated donor (MUD), 7 /8 HLA-MUD, or umbilical cord blood (UCB) HCT. Comparing haploidentical HCT to MSD HCT, we found that OS, leukemia-free survival (LFS), nonrelapse mortality (NRM), relapse, and acute graft-versus-host disease (aGVHD) were not different but chronic GVHD (cGVHD) was higher in MSD HCT. Compared with MUD HCT, OS, LFS, and relapse were not different, but MUD HCT had increased NRM (hazard ratio [HR], 1.42; P = .02), grade 3 to 4 aGVHD (HR, 1.59; P = .005), and cGVHD. Compared with 7/8 UD HCT, LFS and relapse were not different, but 7/8 UD HCT had worse OS (HR, 1.38; P = .01) and increased NRM (HR, 2.13; P ≤ .001), grade 3 to 4 aGVHD (HR, 1.86; P = .003), and cGVHD (HR, 1.72; P ≤ .001). Compared with UCB HCT, late OS, late LFS, relapse, and cGVHD were not different but UCB HCT had worse early OS (≤18 months; HR, 1.93; P < .001), worse early LFS (HR, 1.40; P = .007) and increased incidences of NRM (HR, 2.08; P < .001) and grade 3 to 4 aGVHD (HR, 1.97; P < .001). Haploidentical HCT using PTCy showed no difference in survival but less GVHD compared with traditional MSD and MUD HCT and is the preferred alternative donor HCT option for adults with ALL in complete remission.
Determining support for and barriers to pharmacist‐driven research: Results of a national survey
O'Brien, K. M. , Badowski, Melissa E. , Bartoo, Anna, Peppard, William , Schwarz, Kerry , Sharpe, Abigail R. , Szwak, Jennifer Austin

Mayo Clinic

JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY | September 21, 2021 | Volume: 4 | Issue: 12 | Pages: 1534-1539

10.1002/jac5.1523 Get It

AbstractIntroductionActive engagement in research and scholarly output is challenging for pharmacists following residency training.ObjectivesTo determine the current structure of institutional support for pharmacy research, describe barriers to increasing staff research support and scholarly output, and benchmark best practices.MethodsA national survey was developed and distributed to the Vizient Consortium Director of Pharmacy listserv. The survey was conducted between October 2, 2019 and January 31, 2020 and incorporated 23 base questions assessing seven domains: financial support, study design/conduct support, interdisciplinary support, staff incentives, pharmacy research oversight, best practices, and barriers to research support.ResultsThe survey was distributed to 253 directors of pharmacy and 49 (19%) distinct responses were obtained. Most responders (71%) reported less than 25% of clinical staff were involved in research. Responses indicated most departmental research was driven by residents: 43% reported postgraduate year one (PGY1) and postgraduate year two (PGY2) residents were responsible for at least 75% of research projects. The greatest barriers to conducting research included time (72%), funding (33%), and knowledge/experience (32%). Research support included access to statisticians for data analysis (63%) or study design (57%), development of a pharmacy research committee (55%), and financial support or stipends (45%).ConclusionDespite institutional financial and educational support, the most commonly reported barriers to conducting pharmacy research were time, funding, and knowledge or experience of staff pharmacists.
Less Known Gastrointestinal Manifestations of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome: A Systematic Review of the Literature
Jevtic, Dorde , Dumic, Igor , Nordin, Terri , Singh, Amteshwar , Sulovic, Nadezda, Radovanovic, Milan , Jecmenica, Mladen , Milovanovic, Tamara, Alempijević, Tamara , Jevtic, Djordje , Alempijevic, Tamara , Dumic, Igor , Singh, Amteshwar

Mayo Clinic

Journal of Clinical Medicine | September 21, 2021 | Volume: 10 | Issue: 18 | Pages: 4287

10.3390/jcm10184287 | PMID 34575398 Get It

Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome is a potentially life threatening severe cutaneous drug reaction. Most patients develop eosinophilia, a rash, a fever, lymphadenopathy and variable visceral organ involvement 2–6 weeks following exposure to the inciting medication. Unlike other severe cutaneous drug reactions, internal organ involvement that leads to high mortality is a unique feature of DRESS syndrome. While the liver is the most common internal organ involved, literally every other visceral organ can be affected in this syndrome. The lesser-known gastrointestinal manifestations of this syndrome include esophagitis, gastritis, enteritis, colitis, pancreatitis and a late autoimmune sequela due to pancreatic injury such as fulminant type 1 diabetes mellitus, autoimmune type 1 diabetes mellitus and type 2 diabetes mellitus. While these entities are less common, they are associated with equally severe complications and adverse patient outcomes. In this review, we synthetize data on these rare manifestations using Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The liver, the most common visceral organ involved, has been described as part of DRESS elsewhere and is not included in the scope of this article.
1H Nuclear Magnetic Resonance Spectroscopy-Based Methods for the Quantification of Proteins in Urine
Vučković, Ivan , Đenić, Aleksandar , Charlesworth, M. Cristine , Bobart, Shane A. , Macura, Slobodan , Bobart, Shane, Macura, Slobodan I , Denic, Aleksandar , Vuckovic, Ivan , Charlesworth, M. Cristine , Šuvakov, Milovan , Lieske, John C. , Fervenza, Fernando C.

Mayo Clinic

Analytical Chemistry | September 21, 2021 | Volume: 93 | Issue: 39 | Pages: 13177-13186

10.1021/acs.analchem.1c01618 | PMID 34546699 Get It

Critical appraisal of technologies to assess electrical activity during atrial fibrillation: a position paper from the European Heart Rhythm Association and European Society of Cardiology Working Group on eCardiology in collaboration with the Heart Rhythm
Groot, Natasja M.S. de , Shah, Dipen , Boyle, Patrick M. , Clifford, Gari D. , Dessel, Pascal van, Heinzel, Frank R. , Lambiase, Pier D. , Lumens, Joost , Platonov, Pyotr G. , Ngarmukos, Tachapong , Martí­nez, Juan Pablo , Sánchez, Alejandro Olaya, Takahashi, Yoshihide , Valdigem, Bruno Pereira , Veen, Alle-Jan van der, Vernooy, Kevin , Casado-Arroyo, Rubén , Group, ESC Scientific Document, Linz, Dominik , Svennberg, Emma , Kim, Young‐Hoon , López-Cabanillas, Néstor , Locati, Emanuela T, MacFarlane, Peter, Locati, Emanuela H. , Lambiase, Pier D , de Groot, Natasja M S , Linz, Dominik , Anter, Elad , Deisenhofer, Isabel , Deneke, Thomas , Dessel, Pascal F.H.M. van , Doessel, Olaf , Dilaveris, Polychronis E , Kapa, Suraj , Veen, Alle-Jan van der , Group, ESC Scientific Document, Potter, Tom J. R. De , Dinov, Borislav , Kosiuk, Jędrzej , Neubeck, Lis , Wan, Elaine Y. , Casado-Arroyo, Rubén

Mayo Clinic

EP Europace | September 21, 2021 | Volume: 24 | Issue: 2 | Pages: 313-330

10.1093/europace/euab254 | PMID 34878119 Get It

Abstract We aim to provide a critical appraisal of basic concepts underlying signal recording and processing technologies applied for (i) atrial fibrillation (AF) mapping to unravel AF mechanisms and/or identifying target sites for AF therapy and (ii) AF detection, to optimize usage of technologies, stimulate research aimed at closing knowledge gaps, and developing ideal AF recording and processing technologies. Recording and processing techniques for assessment of electrical activity during AF essential for diagnosis and guiding ablative therapy including body surface electrocardiograms (ECG) and endo- or epicardial electrograms (EGM) are evaluated. Discussion of (i) differences in uni-, bi-, and multi-polar (omnipolar/Laplacian) recording modes, (ii) impact of recording technologies on EGM morphology, (iii) global or local mapping using various types of EGM involving signal processing techniques including isochronal-, voltage- fractionation-, dipole density-, and rotor mapping, enabling derivation of parameters like atrial rate, entropy, conduction velocity/direction, (iv) value of epicardial and optical mapping, (v) AF detection by cardiac implantable electronic devices containing various detection algorithms applicable to stored EGMs, (vi) contribution of machine learning (ML) to further improvement of signals processing technologies. Recording and processing of EGM (or ECG) are the cornerstones of (body surface) mapping of AF. Currently available AF recording and processing technologies are mainly restricted to specific applications or have technological limitations. Improvements in AF mapping by obtaining highest fidelity source signals (e.g. catheter–electrode combinations) for signal processing (e.g. filtering, digitization, and noise elimination) is of utmost importance. Novel acquisition instruments (multi-polar catheters combined with improved physical modelling and ML techniques) will enable enhanced and automated interpretation of EGM recordings in the near future.
Efficacy and safety of ivermectin for the treatment of COVID-19: a systematic review and meta-analysis
Deng, Jiawen , Zhou, Fangwen , Ali, Saif , Heybati, Kiyan , Hou, Wenteng , Huang, Emma , Wong, C Y, Deng, J , Zhou, F

Mayo Clinic

QJM: An International Journal of Medicine | September 21, 2021 | Volume: 114 | Issue: 10 | Pages: 721-732

10.1093/qjmed/hcab247 | PMID 34570241 Get It

Summary Background Ivermectin became a popular choice for COVID-19 treatment among clinicians and the public following encouraging results from pre-print trials and in vitro studies. Early reviews recommended the use of ivermectin based largely on non-peer-reviewed evidence, which may not be robust. This systematic review and meta-analysis assessed the efficacy and safety of ivermectin for treating COVID-19 based on peer-reviewed randomized controlled trials (RCTs) and observational studies (OSs). Methods MEDLINE, EMBASE and PubMed were searched from 1 January 2020 to 1 September 2021 for relevant studies. Outcomes included time to viral clearance, duration of hospitalization, mortality, incidence of mechanical ventilation and incidence of adverse events. RoB2 and ROBINS-I were used to assess risk of bias. Random-effects meta-analyses were conducted. GRADE was used to evaluate quality of evidence. Results Three OSs and 14 RCTs were included in the review. Most RCTs were rated as having some concerns in regards to risk of bias, while OSs were mainly rated as having a moderate risk of bias. Based on meta-analysis of RCTs, the use of ivermectin was not associated with reduction in time to viral clearance, duration of hospitalization, incidence of mortality and incidence of mechanical ventilation. Ivermectin did not significantly increase incidence of adverse events. Meta-analysis of OSs agrees with findings from RCT studies. Conclusions Based on very low to moderate quality of evidence, ivermectin was not efficacious at managing COVID-19. Its safety profile permits its use in trial settings to further clarify its role in COVID-19 treatment. Protocol registration The review was prospectively registered in PROSPERO (CRD42021275302).
Intraoperative fluid management and kidney transplantation outcomes: A retrospective cohort study
Harbell, Monica W. , Kraus, Molly B. , Bucker‐Petty, Skye A., Harbell, Jack W. , Harbell, Monica W , Kraus, Molly B

Mayo Clinic

Clinical Transplantation | September 21, 2021 | Volume: 35 | Issue: 12 | Pages: No page available

10.1111/ctr.14489 | PMID 34546602 Get It

AbstractBackgroundPatients undergoing kidney transplantation traditionally receive liberal amounts of fluid during surgery. However, excessive fluids can lead to fluid overload and ileus. In this retrospective cohort study, we compared the effect of restrictive versus liberal fluid therapy on kidney transplantation outcomes.MethodsPatients who underwent deceased‐donor kidney transplantation at Mayo Clinic from January 2014 to March 2019 were included. Those who received <3 L of intravenous fluids intraoperatively were categorized as “restrictive;” those who received ≥3 L were categorized as “liberal.” The primary outcome was incidence of delayed graft function (DGF). Secondary outcomes included length of stay, readmission within 30 days, time to return of bowel function, and incidence of postoperative complications.ResultsOf the 1171 patients included, 557 were in the restrictive group and 614 in the liberal group. The mean (SD) fluid intake was 2.17 (.54) L in the restrictive group and 3.67 (.68) L in the liberal group (P<.001). There was no difference in DGF (relative risk, 1.03; P = .56), length of stay (P = .34), readmission (P = .80), return of bowel function (P = .71), or other postoperative complications.ConclusionsIntraoperative restrictive fluid therapy during kidney transplantation was not associated with DGF or worse outcomes when compared with liberal fluid therapy.
Enhancing public health and safety by diagnosing and treating obstructive sleep apnea in the transportation industry: an American Academy of Sleep Medicine position statement
Das, Aneesa M., Chang, Judy L., Berneking, Michael , Hartenbaum, Natalie P., Rosekind, Mark R., Ramar, Kannan , Malhotra, Raman K. , Carden, Kelly A., Abbasi-Feinberg, Fariha, Aurora, R. Nisha , Olson, Eric J. , Rosen, Carol L. , Rowley, James A. , Shelgikar, Anita V., Trotti, Lynn Marie , Gurubhagavatula, Indira , Trotti, Lynn Marie , Martin, Jennifer L. , Kapur, Vishesh K.

Mayo Clinic

Journal of Clinical Sleep Medicine | September 21, 2021 | Volume: 18 | Issue: 10 | Pages: 2467-2470

10.5664/jcsm.9670 | PMID 34534065 Get It